>>> Bio-Path Quadruples on Receipt of Cancer-Drug Tech Patent
Bio-Path shares as much as quadrupled. The company received a patent that builds on earlier ones protecting the platform tech for its nanoparticle drugs.
Bio-Path Holdings (BPTH) - shares as much as quadrupled on Wednesday after the biotechnology company said it received a patent for its cancer-treatment technology.
Bio-Path recently traded at $16.75, compared with its Tuesday close at $5.20. It has traded on Wednesday at as much as a 52-week high $24.34. It was trading below $3 in mid-March.
The technology receiving the patent is DNAbilize liposomal delivery and antisense technology, used to develop a portfolio of targeted nucleic acid cancer drugs.
The patent is titled "P-ethoxy nucleic acids for liposomal formulation," Bio-Path said.
“The new patent builds on earlier patents granted that protect the platform technology for DNAbilize, the company’s novel RNAi nanoparticle drugs.”
The U.S. Patent and Trademark Office also has sent notification for a patent related to the company’s lead product candidate, prexigebersen, Bio-Path said.
“Our innovative DNAbilize platform improves upon the drawbacks of traditional approaches, which are limited by the toxicity induced by either the DNA backbone or the lipid delivery,” Chief Executive Peter Nielsen said in a statement.
“DNAbilize overcomes these challenges by combining a neutral charge P-ethoxy DNA backbone with a neutral charge liposome.”
Further, “The result is a high payload liposome with DNA safely delivered inside non-toxic cell membrane-like molecules, allowing us to deliver antisense DNA in high doses to target cells through the blood and lymphatic system with no evidence of toxicity in patients in clinical trials to date, in contrast to other lipid delivery technologies with dose limiting toxicities,” he said.
The P-ethoxy nucleic acids patent “is the third patent in our family of platform intellectual property and offers expanded defense of our DNAbilize platform technology,” Nielsen said.
Blade, I saw your post on GMTX and wondered if you decided to invest? Also saw the bio newsletter post over on Dew's board (link below), and the author mentions 4 stocks involved in the dry macular space. Things looked great until seeing that 20% of the dry macular patients had flipped to 'wet' during treatment (compared to 1% in the placebo group).
Not sure if GMTX's drug will do better, but 20% of patients going wet is no laughing matter since the wet form is devastating. My mom had it, and after several years of Avastin and then Lucentis injections, she ultimately lost most of her vison over a 3 day period. She went from 20/80 to basically blind, what a nightmare. My dad had the dry form and luckily it stayed dry.
With the total lack of current treatments (other than vitamins/minerals), the GMTX drug could be a blockbuster if it can improve on that 20% risk aspect. I think that other drug was from Apellis Pharma -
News 
Market Data 
Discover 
AI
